Incidence of herpes zoster in patients with altered immune function

Infection

Volumn 42, Issue 2, 2014, Pages 325-334

  Chen, S Y ^a   Suaya, J A ^b   Li, Q ^a   Galindo, C M ^b   Misurski, D ^b   Burstin, S ^b   Levin, M J ^c  

^a EVIDERA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Herpes zoster; Immune compromised; Incidence; Persistent post zoster pain

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAID; MEDICARE; MULTIPLE SCLEROSIS; ORGAN TRANSPLANTATION; PERSISTENT POST ZOSTER PAIN; POPULATION; PSORIASIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; AGED; CELLULAR IMMUNITY; EPIDEMIOLOGY; FACTUAL DATABASE; IMMUNOLOGY; MIDDLE AGED; PAIN; PHYSIOLOGY; UNITED STATES; VARICELLA ZOSTER VIRUS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; MALE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84897555328     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0550-8     Document Type: Article

References (40)

1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26:675-97. (Pubitemid 352020491)
2. White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27:781-92.
3. Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30:2047-50.
4. Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Work and productivity loss related to herpes zoster. J Med Econ. 2011;14:639-45.
5. Dworkin RH, White R, O'Connor AB, Hawkins K. Health care expenditure burden of persisting herpes zoster pain. Pain Med. 2008;9:348-53. (Pubitemid 351467890)
6. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39:342-8. (Pubitemid 39050481)
7. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490-6. (Pubitemid 46956185)
8. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605-9.
9. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-53. (Pubitemid 41141008)
10. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133:245-53. (Pubitemid 40439304)
11. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9. (Pubitemid 350060129)
12. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:332-40.
13. Hales C, Harpaz R, Joesoef MR, Bialek SR, editors. Increasing incidence of herpes zoster in the U.S. medicare population aged 65 and older, 1991-2009. San Diego: Infectious Diseases Society of America; 2012.
14. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494-500.
15. Gourishankar S, McDermid J, Jhangri G, Preiksaitis J. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transpl. 2004;4:108-15. (Pubitemid 38155496)
16. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transpl. 2008;27:11-6.
17. Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, et al. Herpes zoster incidence in amulticenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13:15-23.
18. Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537-44.
19. Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:82-90.
20. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current ART era. J Acquir Immune Defic Syndr. 2012;61:203-7.
21. Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S, et al. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis. 2013;13:372.
22. Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfa E. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010;16:119-22.
23. Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66:1177-82.
24. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48:1364-71.
25. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthr Rheum. 2007;57:1431-8. (Pubitemid 350308841)
26. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. J Am Med Assoc. 2009;301:737-44.
27. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-90. (Pubitemid 44880029)
28. Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.
29. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine. 2003;21:2541-7. (Pubitemid 36561347)
30. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001;33:62-9. (Pubitemid 32554504)
31. Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect. 2004;132:1-5. (Pubitemid 38240065)
32. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38-47.
33. Opstelten W, Van Essen GA, Schellevis F, Verheij TJ, Moons KG. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006;16:692-5. (Pubitemid 44190173)
34. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
35. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135:908-13. (Pubitemid 47616471)
36. Toyama N, Shiraki K. Society of the Miyazaki Prefecture D. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053-8.
37. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-9.
38. Di Legami V, Gianino MM, Ciofi degli Atti M, Massari M, Migliardi A, Tomba GS, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25:7598-604. (Pubitemid 47503489)
39. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24:1308-14. (Pubitemid 43222038)
40. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003;70:S24-30. (Pubitemid 36368841)